UA94938C2 - Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты) - Google Patents

Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)

Info

Publication number
UA94938C2
UA94938C2 UAA200812737A UAA200812737A UA94938C2 UA 94938 C2 UA94938 C2 UA 94938C2 UA A200812737 A UAA200812737 A UA A200812737A UA A200812737 A UAA200812737 A UA A200812737A UA 94938 C2 UA94938 C2 UA 94938C2
Authority
UA
Ukraine
Prior art keywords
akaftadine
pharmaceutically acceptable
acceptable salt
treating
clinical symptom
Prior art date
Application number
UAA200812737A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джагдиш Парасрампуриа
Авнер Ингерман
Франс Янссенс
Антон Мегенс
Original Assignee
ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи filed Critical ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи
Publication of UA94938C2 publication Critical patent/UA94938C2/ru

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к офтальмической композиции для лечения или предупреждения аллергических заболеваний и воспаления глаз и их симптомов, содержащей алкафтадин или его фармацевтически приемлемую соль.
UAA200812737A 2006-03-31 2007-03-26 Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты) UA94938C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31

Publications (1)

Publication Number Publication Date
UA94938C2 true UA94938C2 (ru) 2011-06-25

Family

ID=40770601

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200812737A UA94938C2 (ru) 2006-03-31 2007-03-26 Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)

Country Status (3)

Country Link
CN (1) CN101460176B (ru)
AR (1) AR111697A2 (ru)
UA (1) UA94938C2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724149A (zh) * 2016-06-07 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的稠合咪唑环化合物及其药物组合物
CN107854470B (zh) * 2016-09-21 2020-03-27 武汉武药科技有限公司 阿卡他定组合物、其制备方法和用途
EP3740191B1 (en) * 2018-01-18 2021-04-28 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions

Also Published As

Publication number Publication date
CN101460176A (zh) 2009-06-17
AR111697A2 (es) 2019-08-07
CN101460176B (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
SG170044A1 (en) Ocular allergy treatments
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
WO2006097337A3 (en) 11β-HYDROXYSTEROID DEHYDROGENASES
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2007126841A3 (en) Inhibition of alpha-synuclein toxicity
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
HK1210274A1 (en) Methods and ophthalmic devices used in the treatment of ocular allergies
WO2009085271A3 (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
MX342183B (es) Suspension oftalmica para uso ocular.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
WO2008013984A3 (en) Compositions and methods for treating or preventing ophthalmic disease
MY178169A (en) Topical ophthalmic peptide formulation
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2007147868A3 (en) Prevention of muscle atrophy
UA94938C2 (ru) Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)
WO2010107991A3 (en) Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
WO2008067056A3 (en) Method of inhibiting coagulation with human anti-factor va antibodies and use thereof
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
GB0523964D0 (en) The treatment of ophthalmic diseases
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
WO2008063559A3 (en) Methods for using optical agents